Gang Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gang Li has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Aimei Li
Department of Nuclear Medicine, Nanjing Drum Tower Hospital, Nanjing, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
9 shared publications - Baorui Liu
Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China
9 shared publications - Bozhu Chen
Department of Radiology, Nanjing Drum Tower Hospital, Nanjing, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
9 shared publications - Dongsheng Chen
State Key Laboratory of Neurology and Oncology Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, China
9 shared publications - Fan Tong
Department of Oncology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Drum Tower Hospital, Nanjing University of Chinese Medicine, Nanjing, China
9 shared publications - Hao Cheng
Department of Pancreatic and Metabolic Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
9 shared publications
Latest Publications
- Open Access
- 19 March 2026
- Published by Wiley in Small Structures
- Vol. 7 (3)
Engineered Elastin‐Like Polypeptides: Intelligent Self‐Assembling Platforms for Biomedical Application
Elastin‐like polypeptides (ELPs), genetically programmable biomaterials derived from natural tropoelastin, exhibit unique reversible self‐assembly and aggregation behaviors driven by sequence‐encoded phase transitions. These dynamic structural transitions enable ELPs to form diverse supramolecular architectures—including nanoparticles, coacervates, and hydrogels—whose mechanical and physicochemical properties can be precisely tuned by molecular design. In this review, we summarize the characteristics and production methods of ELPs, highlighting their advantages over conventional chemical synthesis and biosynthesis strategies. We then discuss the diverse biomedical platforms based on ELPs, including their use as fusion tags for purification and delivery of peptides, proteins, enzymes, antibodies, and nucleic acids; as conjugates for targeted delivery of chemotherapeutics and imaging agents, and as components of advanced copolymers or smart coacervates construction. In addition, we highlight the applications of ELP‐based hydrogels in tissue regeneration, 3D model construction, and cancer treatment. Furthermore, we introduce the artificial intelligence‐assisted de novo design of ELPs with complex structures and functions. Finally, we provide perspectives on the current challenges and future opportunities of this field, underscoring the promise of ELP‐based biomaterials in driving the next generation of precision medicine.
- 19 March 2026
- Published by Wiley in Small Structures
- Vol. 7 (3)
Open AccessEngineered Elastin‐Like Polypeptides: Intelligent Self‐Assembling Platforms for Biomedical Application
Elastin‐like polypeptides (ELPs), genetically programmable biomaterials derived from natural tropoelastin, exhibit unique reversible self‐assembly and aggregation behaviors driven by sequence‐encoded phase transitions. These dynamic structural transitions enable ELPs to form diverse supramolecular architectures—including nanoparticles, coacervates, and hydrogels—whose mechanical and physicochemical properties can be precisely tuned by molecular design. In this review, we summarize the characteristics and production methods of ELPs, highlighting their advantages over conventional chemical synthesis and biosynthesis strategies. We then discuss the diverse biomedical platforms based on ELPs, including their use as fusion tags for purification and delivery of peptides, proteins, enzymes, antibodies, and nucleic acids; as conjugates for targeted delivery of chemotherapeutics and imaging agents, and as components of advanced copolymers or smart coacervates construction. In addition, we highlight the applications of ELP‐based hydrogels in tissue regeneration, 3D model construction, and cancer treatment. Furthermore, we introduce the artificial intelligence‐assisted de novo design of ELPs with complex structures and functions. Finally, we provide perspectives on the current challenges and future opportunities of this field, underscoring the promise of ELP‐based biomaterials in driving the next generation of precision medicine.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Data from Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring
Purpose:The optimal conversion treatment for patients with borderline resectable pancreatic cancer or locally advanced pancreatic cancer (BRPC/LAPC) remains unclear. In this study, we present the efficacy and safety results of a phase II trial evaluating tislelizumab combined with hypofractionated radiotherapy plus nab-paclitaxel/gemcitabine (THAG) in patients with BRPC/LAPC (ChiCTR2000032955, NCT05634564).Patients and Methods:This phase II trial enrolled 56 patients with BRPC/LAPC (BRPC: 17, 30.4%; LAPC: 39, 69.6%). Participants received tislelizumab plus nab-paclitaxel/gemcitabine (AG) in 21-day cycles. Nonprogressing patients received concurrent radiotherapy during the third chemotherapy cycle. After four treatment cycles, a multidisciplinary team assessed eligibility for radical surgery. Dynamic biomolecular profiling was performed.Results:Fifty-six eligible patients were enrolled. The objective response rate was 51.8% [95% confidence interval (CI), 38.0%–65.3%]. Median progression-free survival (mPFS) was 13.2 months (95% CI, 11.6–19.4 months), and median overall survival (mOS) was 21.3 months [95% CI, 18.8–not reached (NR)]. Among 30 patients who met criteria for surgical resectability, 22 patients (22/56, 39.3%) underwent radical resection, comprising nine patients with BRPC (9/17, 52.9%) and 13 patients with LAPC (13/39, 33.3%). The margin-negative resection rate reached 90.9% (95% CI, 70.8%–98.9%), and the mOS of patients who underwent surgery was 34.0 months (95% CI, 20.1–NR). Grade ≥3 adverse events (AE) occurred in 33/56 patients (58.9%). Dynamic biomarker exploration revealed that baseline IL6 level (>5 pg/mL) predicted better PFS. Moreover, circulating tumor DNA (ctDNA) status and clearance demonstrated superior survival.Conclusions:The THAG regimen as preoperative therapy showed encouraging clinical activity with a manageable safety profile. Dynamic biomarker findings reveal potential for guiding precision treatment strategies with THAG.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring
Purpose:The optimal conversion treatment for patients with borderline resectable pancreatic cancer or locally advanced pancreatic cancer (BRPC/LAPC) remains unclear. In this study, we present the efficacy and safety results of a phase II trial evaluating tislelizumab combined with hypofractionated radiotherapy plus nab-paclitaxel/gemcitabine (THAG) in patients with BRPC/LAPC (ChiCTR2000032955, NCT05634564).Patients and Methods:This phase II trial enrolled 56 patients with BRPC/LAPC (BRPC: 17, 30.4%; LAPC: 39, 69.6%). Participants received tislelizumab plus nab-paclitaxel/gemcitabine (AG) in 21-day cycles. Nonprogressing patients received concurrent radiotherapy during the third chemotherapy cycle. After four treatment cycles, a multidisciplinary team assessed eligibility for radical surgery. Dynamic biomolecular profiling was performed.Results:Fifty-six eligible patients were enrolled. The objective response rate was 51.8% [95% confidence interval (CI), 38.0%–65.3%]. Median progression-free survival (mPFS) was 13.2 months (95% CI, 11.6–19.4 months), and median overall survival (mOS) was 21.3 months [95% CI, 18.8–not reached (NR)]. Among 30 patients who met criteria for surgical resectability, 22 patients (22/56, 39.3%) underwent radical resection, comprising nine patients with BRPC (9/17, 52.9%) and 13 patients with LAPC (13/39, 33.3%). The margin-negative resection rate reached 90.9% (95% CI, 70.8%–98.9%), and the mOS of patients who underwent surgery was 34.0 months (95% CI, 20.1–NR). Grade ≥3 adverse events (AE) occurred in 33/56 patients (58.9%). Dynamic biomarker exploration revealed that baseline IL6 level (>5 pg/mL) predicted better PFS. Moreover, circulating tumor DNA (ctDNA) status and clearance demonstrated superior survival.Conclusions:The THAG regimen as preoperative therapy showed encouraging clinical activity with a manageable safety profile. Dynamic biomarker findings reveal potential for guiding precision treatment strategies with THAG.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring
Representativeness of Study Participants
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring
Representativeness of Study Participants
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring
Multivariable COX analysis of PFS and OS
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring
Multivariable COX analysis of PFS and OS
- 1 December 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (3) , 516-527
Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring
Purpose: The optimal conversion treatment for patients with borderline resectable pancreatic cancer or locally advanced pancreatic cancer (BRPC/LAPC) remains unclear. In this study, we present the efficacy and safety results of a phase II trial evaluating tislelizumab combined with hypofractionated radiotherapy plus nab-paclitaxel/gemcitabine (THAG) in patients with BRPC/LAPC (ChiCTR2000032955, NCT05634564). Patients and Methods: This phase II trial enrolled 56 patients with BRPC/LAPC (BRPC: 17, 30.4%; LAPC: 39, 69.6%). Participants received tislelizumab plus nab-paclitaxel/gemcitabine (AG) in 21-day cycles. Nonprogressing patients received concurrent radiotherapy during the third chemotherapy cycle. After four treatment cycles, a multidisciplinary team assessed eligibility for radical surgery. Dynamic biomolecular profiling was performed. Results: Fifty-six eligible patients were enrolled. The objective response rate was 51.8% [95% confidence interval (CI), 38.0%–65.3%]. Median progression-free survival (mPFS) was 13.2 months (95% CI, 11.6–19.4 months), and median overall survival (mOS) was 21.3 months [95% CI, 18.8–not reached (NR)]. Among 30 patients who met criteria for surgical resectability, 22 patients (22/56, 39.3%) underwent radical resection, comprising nine patients with BRPC (9/17, 52.9%) and 13 patients with LAPC (13/39, 33.3%). The margin-negative resection rate reached 90.9% (95% CI, 70.8%–98.9%), and the mOS of patients who underwent surgery was 34.0 months (95% CI, 20.1–NR). Grade ≥3 adverse events (AE) occurred in 33/56 patients (58.9%). Dynamic biomarker exploration revealed that baseline IL6 level (>5 pg/mL) predicted better PFS. Moreover, circulating tumor DNA (ctDNA) status and clearance demonstrated superior survival. Conclusions: The THAG regimen as preoperative therapy showed encouraging clinical activity with a manageable safety profile. Dynamic biomarker findings reveal potential for guiding precision treatment strategies with THAG.
- 1 December 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (3) , 516-527
Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring
Purpose: The optimal conversion treatment for patients with borderline resectable pancreatic cancer or locally advanced pancreatic cancer (BRPC/LAPC) remains unclear. In this study, we present the efficacy and safety results of a phase II trial evaluating tislelizumab combined with hypofractionated radiotherapy plus nab-paclitaxel/gemcitabine (THAG) in patients with BRPC/LAPC (ChiCTR2000032955, NCT05634564). Patients and Methods: This phase II trial enrolled 56 patients with BRPC/LAPC (BRPC: 17, 30.4%; LAPC: 39, 69.6%). Participants received tislelizumab plus nab-paclitaxel/gemcitabine (AG) in 21-day cycles. Nonprogressing patients received concurrent radiotherapy during the third chemotherapy cycle. After four treatment cycles, a multidisciplinary team assessed eligibility for radical surgery. Dynamic biomolecular profiling was performed. Results: Fifty-six eligible patients were enrolled. The objective response rate was 51.8% [95% confidence interval (CI), 38.0%–65.3%]. Median progression-free survival (mPFS) was 13.2 months (95% CI, 11.6–19.4 months), and median overall survival (mOS) was 21.3 months [95% CI, 18.8–not reached (NR)]. Among 30 patients who met criteria for surgical resectability, 22 patients (22/56, 39.3%) underwent radical resection, comprising nine patients with BRPC (9/17, 52.9%) and 13 patients with LAPC (13/39, 33.3%). The margin-negative resection rate reached 90.9% (95% CI, 70.8%–98.9%), and the mOS of patients who underwent surgery was 34.0 months (95% CI, 20.1–NR). Grade ≥3 adverse events (AE) occurred in 33/56 patients (58.9%). Dynamic biomarker exploration revealed that baseline IL6 level (>5 pg/mL) predicted better PFS. Moreover, circulating tumor DNA (ctDNA) status and clearance demonstrated superior survival. Conclusions: The THAG regimen as preoperative therapy showed encouraging clinical activity with a manageable safety profile. Dynamic biomarker findings reveal potential for guiding precision treatment strategies with THAG.